Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Phase 1 Completed 22 enrolled Case Comprehensive Cancer Center National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy in treating patients who have advanced solid tumors.

Timeline

Start: 2000-12
Primary completion: 2003-11
Completion: 2005-04

Publications

Results Krishnamurthi SS, Brell JM, Hoppel CL, Egorin MJ, Weaver KC, Li X, Ingalls ST, Zuhowski EG, Schluchter MD, Dowlati A, Cooney MM, Gibbons J, Overmoyer BA, Ivy SP, Remick SC. Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine. Cancer Chemother Pharmacol. 2009 Feb;63(3):441-50. doi: 10.1007/s00280-008-0754-2. Epub 2008 Apr 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Capecitabine	Small molecule	450 mg	Oral
Subject	Capecitabine	Small molecule	1000 mg	Oral
Subject	Irinotecan	Small molecule	40 mg/m2	Intravenous
Subject	Irinotecan	Small molecule	50 mg/m2	Intravenous
Subject	Oxaliplatin	Small molecule	60 mg/m2	Intravenous

Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Summary

Timeline

Publications

Drugs

Indications